The company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder. CAPLYTA is noted for its unique mechanism of action that modulates dopamine, serotonin, and glutamate levels simultaneously, with analysts projecting that peak sales could exceed $5 billion annually.
Cyborg Score Rationale
ITCI delivered exceptional commercial success with its flagship product CAPLYTA, achieving significant FDA approvals and projected peak sales exceeding $5 billion. The company's acquisition by Johnson & Johnson at $15 billion in early 2025 validates its strategic value and innovative approach to CNS drug development. However, as a now-acquired company, growth is bounded by J&J's integration strategy.
Top Insights
CAPLYTA achieved FDA approvals for both schizophrenia and bipolar depression, representing a broad commercial opportunity in CNS markets
Acquisition by Johnson & Johnson (early 2025) at $132/share provides validation of the company's technology and market positioning
Company maintains a robust pipeline including Lenrispodun (ITI-214) for Parkinson's disease and heart failure, plus additional candidates in Phase III development
Intracellular signaling approach differentiates CAPLYTA from traditional antipsychotics, targeting higher efficacy with fewer metabolic side effects
Named Competitors
Antipsychotics/Bipolar Treatments — Leading antipsychotic and neuropsychiatric treatments
CNS Therapeutics — Competing neuropsychiatric and CNS drug developer
Neuropsychiatric Therapeutics — Alternative CNS disorder treatment solutions
Recent Developments
(Early 2025) Johnson & Johnson completed acquisition of Intra-Cellular Therapies for approximately $15 billion
(Phase III) Lumateperone in Phase III clinical trials for bipolar depression and autism spectrum disorder treatment
(Development) ITI-214 (Lenrispodun) being investigated for Parkinson's disease and heart failure
Open the full interactive Intra-Cellular Therapies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.